Sugi Predict

Sugi Predict / Compounds / SCHEMBL735027

SCHEMBL735027

SCHEMBL735027

OCCc1coc2ccccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 2/20 0.59
▸ CA2 P00918 1/20 0.47
▸ PSMB5 P28074 5/20 0.43
▸ PSMB8 P28062 1/20 0.43
▸ HDAC3 O15379 1/20 0.42
▸ HDAC4 P56524 1/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ HDAC7 Q8WUI4 1/20 0.42
▸ HDAC2 Q92769 1/20 0.42
▸ HDAC10 Q969S8 1/20 0.42
▸ HDAC11 Q96DB2 1/20 0.42
▸ HDAC8 Q9BY41 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ HDAC9 Q9UKV0 1/20 0.42
▸ HDAC5 Q9UQL6 1/20 0.42
▸ CYP11B1 P15538 2/20 0.41
▸ CYP11B2 P19099 2/20 0.41
▸ CYP17A1 P05093 1/20 0.41
▸ CYP19A1 P11511 1/20 0.41
▸ IL4I1 Q96RQ9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5239989 0.89 MAOB (0.56) MAOBCA2PSMB5PSMB8HDAC3
SCHEMBL7827866 0.88 CA2 (0.57) MAOBCA2PSMB5PSMB8HDAC3
SCHEMBL5763492 0.87 MAOB (0.54) MAOBCA2PSMB5PSMB8HDAC3
SCHEMBL2091217 0.85 MAOB (0.53) MAOBCA2PSMB5PSMB8HDAC3
SCHEMBL6511946 0.85 MAOB (0.71) MAOBCA2PSMB5PSMB8CYP11B1
SCHEMBL8788617 0.80 CA2 (0.46) MAOBCA2PSMB5PSMB8DRD2
SCHEMBL1252500 0.80 CA2 (0.51) MAOBCA2PSMB5PSMB8CYP11B1
SCHEMBL734528 0.80 MAOB (0.50) MAOBCA2PSMB5PSMB8HDAC3
SCHEMBL734287 0.80 MAOB (0.50) MAOBCA2PSMB5PSMB8HDAC3
SCHEMBL7360353 0.80 MAOB (0.50) MAOBCA2PSMB5PSMB8HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113122062-A Quantum dot ink and preparation method of quantum dot film TCL集团股份有限公司 2021-07-16 — — CN claimed
US-20250346613-A1 BORIC ACID PROTEASOME INHIBITOR AND USE THEREOF ARTIVILA BIOPHARMA (CN) 2025-11-13 — — US disclosed
CN-119930620-A Tetrafused ring compound, preparation method, pharmaceutical composition and application thereof 和径医药科技（上海）有限公司 2025-05-06 — — CN disclosed
US-20250122213-A1 OPIOID RECEPTOR MODULATORS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-04-17 — — US disclosed
EP-4516796-A1 BORIC ACID PROTEASOME INHIBITOR AND USE THEREOF Artivila Biopharma (CN) 2025-03-05 — — EP disclosed
US-12195478-B2 Opioid receptor modulators THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-01-14 — — US disclosed
EP-4487913-A2 OPIOID RECEPTOR MODULATORS The Trustees Of Columbia University In The City Of New York (US) 2025-01-08 — — EP disclosed
EP-3224261-B1 OPIOID RECEPTOR MODULATORS UNIV COLUMBIA (US) 2024-09-18 — — EP disclosed
US-11840541-B2 Opioid receptor modulators THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-12-12 — — US disclosed
US-11840541-B2 Opioid receptor modulators THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-12-12 — — US disclosed
US-6300340-B1 USEFUL FOR THERAPY OF CANCER AND SOLID TUMORS ADIR ET COMPAGNIE (FR) 2001-10-09 — — US disclosed
EP-1122254-A2 4-Sulfonamide piperidine derivatives, method for their preparation and phamaceutical compositions containing them ADIR ET COMPAGNIE (FR) 2001-08-08 — — EP disclosed
US-6162822-A Bisimide compounds ADIR ET COMPAGNIE (FR) 2000-12-19 — — US disclosed
EP-0820985-B1 Bis imide derivatives, process for their preparation and pharmaceutical compositions containing them ADIR (FR) 2000-08-30 — — EP disclosed
US-5854273-A Bisimide compounds ADIR ET COMPAGNIE (FR) 1998-12-29 — — US disclosed
EP-0820985-A1 Bis imide derivatives, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1998-01-28 — — EP disclosed
EP-0009780-B1 OCTAHYDRO-1H-BENZO(4,5)FURO(3,2-E)ISOQUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM E.I. DU PONT DE NEMOURS AND COMPANY (US) 1982-02-24 — — EP disclosed
US-4260761-A Intermediates for the preparation of octahydro-1H-benzo[4,5]furo[3,2,-e]-isoquinoline analgesic and narcotic antagonistic compounds E. I. DU PONT DE NEMOURS AND COMPANY (US) 1981-04-07 — — US disclosed
US-4243668-A Octahydro-1H-benzo[4,5]furo[3,2-e]-isoquinoline analgesic and narcotic antagonistic compounds E. I. DU PONT DE NEMOURS AND COMPANY (US) 1981-01-06 — — US disclosed
EP-0009780-A2 Octahydro-1H-benzo(4,5)furo(3,2-e)isoquinoline derivatives, process for their preparation and pharmaceutical compositions containing them E.I. DU PONT DE NEMOURS AND COMPANY (US) 1980-04-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12195478-B2 Opioid receptor modulators OPRM1, OPRL1, OPRD1 MAOB 585/4885CA2 2833/4885PSMB5 1136/4885
US-20250346613-A1 BORIC ACID PROTEASOME INHIBITOR AND USE THEREOF PSMA1, PSMB11, PSMB1 MAOB 2497/4885CA2 3379/4885PSMB5 12/4885
US-20250122213-A1 OPIOID RECEPTOR MODULATORS OPRM1, OPRL1, OPRD1 MAOB 585/4885CA2 2833/4885PSMB5 1136/4885
US-11840541-B2 Opioid receptor modulators OPRM1, OPRL1, OPRD1 MAOB 564/4885CA2 2632/4885PSMB5 1888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.